First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States

First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States

Background: Various therapeutic strategies are available for the first-line treatment of patients with advanced hepatocellular carcinoma (aHCC). But which approach is the most cost-effective remains uncertain. Objectives: This study aims to evaluate the cost-effectiveness of first-line strategies in...

Full description

Bibliographic Details
Main Authors:	Ke-Xin Sun, Shan-Shan Cao, Feng-Hao Shi, Yue Guan, Meng Tang, Mei-na Zhao, Yu-Fan Jian, Bin Cui, Zhi-Yan Li, Jing-Wen Wang, Feng Yu, Yi Ding
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-12-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/17562848221140662

Similar Items

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
by: Qiuping Chen, et al.
Published: (2024-01-01)

A meta‐analysis and cost‐minimization analysis of bivalirudin versus heparin in high‐risk patients for percutaneous coronary intervention
by: Ke‐Xin Sun, et al.
Published: (2021-05-01)

Promising first‐line immuno‐combination therapies for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
by: Feng Wen, et al.
Published: (2024-08-01)

Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma
by: Weiting Liao, et al.
Published: (2024-09-01)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
by: Ke-Xin Sun, et al.
Published: (2021-10-01)

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
by: Liting wang, et al.
Published: (2023-01-01)

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
by: Liting Wang, et al.
Published: (2023-01-01)

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
by: Maximilian Sieg, et al.
Published: (2020-04-01)

Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
by: Chien-Yu Tseng, et al.
Published: (2023-11-01)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
by: Ying He, et al.
Published: (2023-09-01)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Yan Li, et al.
Published: (2022-07-01)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022-11-01)

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis
by: Guiyuan Xiang, et al.
Published: (2024-11-01)

Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024-03-01)

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
by: Wei Li, et al.
Published: (2023-09-01)

Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis
by: Kun Liu, et al.
Published: (2023-01-01)

Protocol for analysis of plasma proteomes from patients with hepatocellular carcinoma receiving combination therapy
by: Zhi-Feng Pan, et al.
Published: (2024-12-01)

Transcriptome Analysis Revealed a Highly Connected Gene Module Associated With Cirrhosis to Hepatocellular Carcinoma Development
by: Shan Shan, et al.
Published: (2019-04-01)

Noninvasive imaging-based machine learning algorithm to identify progressive disease in advanced hepatocellular carcinoma receiving second-line systemic therapy
by: Wei Dong, et al.
Published: (2023-07-01)

Comprehensive analysis of the prognostic value and functions of prefoldins in hepatocellular carcinoma
by: Shanjia Ke, et al.
Published: (2022-11-01)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022-03-01)

Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma
by: Mei-Mei Li, et al.
Published: (2019-08-01)

Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Lu Li, et al.
Published: (2022-06-01)

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
by: Maple Ye Feng, et al.
Published: (2022-08-01)

Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma
by: Hanrui Zheng, et al.
Published: (2023-10-01)

Stochastic Differential Game Model Analysis of Emission-Reduction Technology Under Cost-Sharing Contracts in the Carbon Trading Market
by: Qiang Hou, et al.
Published: (2020-01-01)

The clinical management of hepatocellular carcinoma in China: Progress and challenges
by: Shan Shan, et al.
Published: (2023-04-01)

ROCK is involved in vasculogenic mimicry formation in hepatocellular carcinoma cell line.
by: Ji-Gang Zhang, et al.
Published: (2014-01-01)

Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
by: Amir Shlomai, et al.
Published: (2019-09-01)

Comprehensive analysis of the correlations of S100B with hypoxia response and immune infiltration in hepatocellular carcinoma
by: Jia Yan, et al.
Published: (2022-03-01)

CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors
by: Zhe Huang, et al.
Published: (2023-03-01)

New insights into fibrotic signaling in hepatocellular carcinoma
by: Liang Shan, et al.
Published: (2023-11-01)

Identification of disulfidptosis-related genes with immune infiltration in hepatocellular carcinoma
by: Xiao-min Li, et al.
Published: (2023-08-01)

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
by: Shuling Chen, et al.
Published: (2018-04-01)

Comparative analysis of TGF-β/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines.
by: Johanna Dzieran, et al.
Published: (2013-01-01)

Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
by: Yu-Yun Shao, et al.
Published: (2022-12-01)

Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma
by: Yuanfei Lu, et al.
Published: (2022-08-01)

The association between MTHFR gene polymorphisms and hepatocellular carcinoma risk: a meta-analysis.
by: Xue Qin, et al.
Published: (2013-01-01)

Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
by: Supachaya Sriphoosanaphan, et al.
Published: (2024-01-01)

Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma
by: Feng Qi, et al.
Published: (2023-01-01)